Related Experiment Video

Updated: Oct 3, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
07:35

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes

S Hägg1, O Spigset, H A Lakso

  • 1Division of Clinical Pharmacology, Norrland University Hospital, Umeå, Sweden. staffan.hagg@pharm.umu.se

European Journal of Clinical Pharmacology
|November 9, 2001
PubMed
Abstract

Insights

This study found that neither CYP1A2 nor CYP2D6 significantly impacts olanzapine metabolism. Olanzapine

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Enzyme Kinetics

Background:

  • Limited data suggest CYP1A2 and CYP2D6 involvement in olanzapine metabolism.
  • Understanding these enzyme roles is crucial for predicting drug disposition.

Purpose of the Study:

  • To investigate the in vivo role of CYP1A2 and CYP2D6 in olanzapine metabolism.
  • To determine if genetic variations in these enzymes affect olanzapine pharmacokinetics.

Main Methods:

  • Seventeen healthy male volunteers (5 CYP2D6 poor metabolizers, 12 extensive metabolizers) received a single 7.5 mg oral dose of olanzapine.
  • CYP1A2 activity was assessed using caffeine and paraxanthine ratios.
  • Olanzapine serum concentrations were measured over 96 hours via gas chromatography.

Main Results:

  • Significant inter-individual variability in olanzapine oral clearance and Cmax was observed.
  • No significant correlation was found between CYP1A2 activity and olanzapine oral clearance.
  • No significant differences in olanzapine pharmacokinetic parameters were detected between CYP2D6 poor and extensive metabolizers.

Conclusions:

  • CYP1A2 does not appear to play a dominant role in the biotransformation of a single dose of olanzapine.
  • CYP2D6 genetic polymorphism does not significantly influence the pharmacokinetics of olanzapine after a single oral dose.
  • Neither enzyme is a major determinant of olanzapine disposition in vivo.

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...